Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 3.14 EUR -1.26% Market Closed
Market Cap: 510.3m EUR

Wall Street
Price Targets

VLA Price Targets Summary
Valneva SE

Wall Street analysts forecast VLA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VLA is 7.43 EUR with a low forecast of 2.98 EUR and a high forecast of 10.5 EUR.

Lowest
Price Target
2.98 EUR
5% Downside
Average
Price Target
7.43 EUR
137% Upside
Highest
Price Target
10.5 EUR
234% Upside
Valneva SE Competitors:
Price Targets
BSLN
Basilea Pharmaceutica AG
79% Upside
COV
Covalon Technologies Ltd
95% Upside
MSB
Mesoblast Ltd
53% Upside
ASND
Ascendis Pharma A/S
37% Upside
EXAS
Exact Sciences Corp
63% Upside
MRNA
Moderna Inc
61% Upside
CYTK
Cytokinetics Inc
84% Upside
MCRB
Seres Therapeutics Inc
519% Upside

Revenue
Forecast

Revenue Estimate
Valneva SE

For the last 8 years the compound annual growth rate for Valneva SE's revenue is 9%. The projected CAGR for the next 4 years is 29%.

9%
Past Growth
29%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Valneva SE

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
15%
Average Beat

Net Income
Forecast

Net Income Estimate
Valneva SE

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-17%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VLA's stock price target?
Price Target
7.43 EUR

According to Wall Street analysts, the average 1-year price target for VLA is 7.43 EUR with a low forecast of 2.98 EUR and a high forecast of 10.5 EUR.

What is Valneva SE's Revenue forecast?
Projected CAGR
29%

For the last 8 years the compound annual growth rate for Valneva SE's revenue is 9%. The projected CAGR for the next 4 years is 29%.

Back to Top